Update shared on 28 Oct 2025
Fair value Increased 14%Beachbody Company's analyst price target has been revised upward from $8.50 to $9.67, as analysts cite expectations of renewed revenue growth and improving profit margins. These outlooks are supported by the company's established position in wellness and the ongoing changes in market dynamics.
Analyst Commentary
Recent coverage of Beachbody Company has highlighted both optimism and caution among market observers as the company works to transition from years of revenue decline to renewed growth.
Bullish Takeaways- Bullish analysts anticipate a swing toward revenue growth, pointing to a turnaround in performance after a challenging period.
- The company's established brands in workout videos and nutritional supplements are viewed as strong foundations, supporting its competitive position in the wellness industry.
- Shifting market dynamics, including increased attention on overall wellness beyond weight loss, present new opportunities for Beachbody to address gaps related to muscle health and nutrition.
- Improving profit margins and an upwardly revised price target indicate renewed confidence in Beachbody's ability to execute its strategy and deliver value to shareholders.
- Bears remain cautious regarding the impact of broader weight loss trends, such as the popularity of GLP-1 medications, which could affect demand for traditional wellness products.
- The company's history of revenue decline prompts skepticism about the durability of the anticipated growth momentum.
- Analysts highlight potential challenges in maintaining consistent profitability, especially in an evolving competitive landscape.
What's in the News
- BODi released The Power of 4, a 90-day program created by P90X trainer Tony Horton, combining fitness, nutrition, supplementation, and mindfulness for well-rounded health. The program includes sessions from 10 to 70 minutes, adjustable for time and fitness level, and introduces new features for session flexibility. (Key Developments)
- BODi launched Super Trainer Subscriptions, letting users access Autumn Calabrese's or Shaun T's complete program libraries for $9.99 per month, as well as a new monthly plan for the entire BODi catalog with a 7-day free trial. (Key Developments)
- BODi added Belle Vitale, a hormone health solution for women, and Track Pilates, an affordable, studio-quality Pilates program, to its platform. Three new vegan Shakeology flavors were also introduced. (Key Developments)
- The Beachbody Company was added to the NASDAQ Composite Index. (Key Developments)
- Primary exchange listing for The Beachbody Company will move to Nasdaq Capital Market from NYSE on September 3, 2025. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has risen from $8.50 to $9.67, reflecting increased confidence in Beachbody's valuation.
- Discount Rate edged down slightly from 8.43% to 8.38%, indicating a marginal decrease in perceived risk or required return.
- Revenue Growth projection, while still negative, has improved from -22.97% to -14.32%. This shows an expectation of a slower decline in sales.
- Net Profit Margin forecast increased modestly from 11.68% to 12.15%. This suggests analysts anticipate improved profitability.
- Future P/E ratio estimate decreased from 4.37x to 3.47x, which indicates the stock is viewed as more attractively priced relative to future earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
